Clinical Trial Update: An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes [Phase 3]

View source ↗

Summary

Open-label extension study of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Epilepsy
• Lennox-gastaut Syndrome

Drugs mentioned

• cannabidiol (GWP42003-P) (cannabidiol)

Snippet

Sponsor: GW Research Ltd | Conditions: Epilepsy, Dravet Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2022-02-03